Author: David Goldstein

While buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for NASH, a severe form of non-alcoholic fatty liver disease, has posted impressive clinical trial results – and, if ultimately successful, “needs only to gobble up a small portion of the total NASH market to become a mega-blockbuster.” For more, CLICK HERE.

The biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that surge is sustainable or justified, and what the best way to play the stock (and its counterparts) may be. For more, CLICK HERE.

“Understandably, investors have taken a more cautious approach when navigating the confused financial environment, but focus is locking in on the biotech sector as it has been able to withstand the COVID-19-induced pressure on the market,” notes the author of today’s article. She proceeds to highlight three “Strong Buy”-rated biotech stocks trading for less than $5 a share that, with upside potential in the 500% to 700% range based on analyst price targets, possess “explosive upside potential.” For more, CLICK HERE.

In the current market environment, the author of today’s article notes that “As a stock picker, it’s important to find areas where the risk and reward proposition is more positive,” and advises that “One of the areas where this is best exhibited is with emerging markets.” He proceeds to highlight three emerging market stocks trading at big discounts based on a number of metrics. For these three stocks, CLICK HERE.

The “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus market sell-off), leads the author to recommend investors keep this company on their radars for potential buy the dip opportunities. For the biotech stock in question, CLICK HERE.

Biotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however, pointing to “two very important names” in the aforementioned ETF that “are starting to break down.” For more, CLICK HERE.

It’s the most popular investing theme this year: COVID-19 vaccine producers. However, the recent reversal of fortunes for the stock of one biotech firm – whose stock had nearly tripled since the beginning of March when the firm announced it was working on a vaccine for the novel coronavirus – illustrates the risk involved with “chasing vaccine hype”. For more, CLICK HERE.

Anticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage.” As such, she proceeds to highlight two “Strong Buy” rated biotech penny stocks with “sky-scraping upside potential”. For more, CLICK HERE.

When it comes to the nascent – but rapidly growing – gene editing space, the author of today’s article notes that “sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish.” With the market for gene editing therapies expected to grow by over 18% annually, he highlights two of the most promising gene editing stocks for biotech investors to consider. For more, CLICK HERE.

Cannabis investors who bet that marijuana stocks would benefit from an increase in demand for cannabis products during the coronavirus lockdowns have largely been disappointed. As today’s article notes, even if demand for marijuana did rise with people stuck at home, “it hasn’t translated to gains for major cannabis producers.” Is more disappointment ahead from marijuana stocks? For more, CLICK HERE.